Healthcare IT News October 22, 2020
At a meeting of the agency’s Patient Engagement Advisory Committee, officials stressed the necessity of ensuring there’s diversity in the data used to train algorithms.
The U.S. Food and Drug Administration on Thursday convened a public meeting of its Patient Engagement Advisory Committee to discuss issues regarding artificial intelligence and machine learning in medical devices.
“Devices using AI and ML technology will transform healthcare delivery by increasing efficiency in key processes in the treatment of patients,” said Dr. Paul Conway, PEAC chair and chair of policy and global affairs of the American Association of Kidney Patients.
As Conway and others noted during the panel, AI and ML systems may have algorithmic biases and lack transparency – potentially leading, in turn,...